Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has been assigned a consensus rating of “Moderate Buy” from the five research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $18.00.

ENTA has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. Wall Street Zen raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 19th. Finally, JMP Securities raised their price target on Enanta Pharmaceuticals from $23.00 to $24.00 and gave the stock a “market outperform” rating in a research note on Tuesday, June 3rd.

Enanta Pharmaceuticals Price Performance

Shares of ENTA opened at $7.50 on Tuesday. The firm has a market cap of $160.33 million, a P/E ratio of -1.52 and a beta of 0.76. The stock has a 50 day simple moving average of $5.57 and a two-hundred day simple moving average of $6.14. Enanta Pharmaceuticals has a 1 year low of $4.09 and a 1 year high of $17.24.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.04) by ($0.02). The firm had revenue of $14.93 million during the quarter, compared to analysts’ expectations of $15.96 million. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. On average, equities analysts anticipate that Enanta Pharmaceuticals will post -4.65 earnings per share for the current year.

Institutional Trading of Enanta Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC raised its holdings in Enanta Pharmaceuticals by 50.2% in the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after purchasing an additional 449,945 shares in the last quarter. RA Capital Management L.P. bought a new position in Enanta Pharmaceuticals in the fourth quarter worth $5,968,000. Marshall Wace LLP raised its holdings in Enanta Pharmaceuticals by 9.3% in the fourth quarter. Marshall Wace LLP now owns 930,087 shares of the biotechnology company’s stock worth $5,348,000 after purchasing an additional 79,197 shares in the last quarter. Acadian Asset Management LLC raised its holdings in Enanta Pharmaceuticals by 2.1% in the first quarter. Acadian Asset Management LLC now owns 867,037 shares of the biotechnology company’s stock worth $4,782,000 after purchasing an additional 17,613 shares in the last quarter. Finally, Stonepine Capital Management LLC raised its holdings in Enanta Pharmaceuticals by 78.0% in the first quarter. Stonepine Capital Management LLC now owns 590,742 shares of the biotechnology company’s stock worth $3,261,000 after purchasing an additional 258,842 shares in the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.